title: Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience.
abstract: Acute hepatitis B progresses to liver failure with the need of liver transplantation in about 1% of cases. We treated patients with severe acute or fulminant hepatitis B with lamivudine in an attempt to prevent hepatitis B virus (HBV) reinfection after potential liver transplantation. Since September 2000, 17 patients with severe acute or fulminant HBV infection were treated with 100 or 150 mg lamivudine daily once we had evidence for a severe course as indicated by an INR >2.0. These were compared to a historic control from our unit and to external patients. Fourteen of the 17 patients (82.4%) survived with full recovery without liver transplantation. All these 14 individuals cleared HBsAg on lamivudine within less than 6 months. Twelve patients recovered quickly as indicated by a normalized prothrombin time within 1 week while two patients had a more prolonged course. None of the patients showed an adverse event. Three patients requiring transplantation despite lamivudine therapy had more advanced disease on admission, of whom one had additionally ingested paracetamol (acetaminophen) while the second was already HBV-DNA negative by polymerase chain reaction on admission. The lamivudine treated patients had significant higher frequency of survival without liver transplantation 82.4 vs 20% (4/20) in the historic control (P < 0.001). Similar data were derived from external centres using lamivudine (15/20, 75%). Lamivudine is safe in patients with severe acute or fulminant hepatitis B, leading to fast recovery with the potential to prevent liver failure and liver transplantation when administered early enough.
authors.affiliation: Medical Clinic and Policlinic II, University Leipzig, Germany. hans.tillmann@medizin.uni-leipzig.de
authors.forename: H L
authors.initials: HL
authors.lastname: Tillmann
authors.forename: J
authors.initials: J
authors.lastname: Hadem
authors.forename: L
authors.initials: L
authors.lastname: Leifeld
authors.forename: K
authors.initials: K
authors.lastname: Zachou
authors.forename: A
authors.initials: A
authors.lastname: Canbay
authors.forename: C
authors.initials: C
authors.lastname: Eisenbach
authors.forename: I
authors.initials: I
authors.lastname: Graziadei
authors.forename: J
authors.initials: J
authors.lastname: Encke
authors.forename: H
authors.initials: H
authors.lastname: Schmidt
authors.forename: W
authors.initials: W
authors.lastname: Vogel
authors.forename: A
authors.initials: A
authors.lastname: Schneider
authors.forename: U
authors.initials: U
authors.lastname: Spengler
authors.forename: G
authors.initials: G
authors.lastname: Gerken
authors.forename: G N
authors.initials: GN
authors.lastname: Dalekos
authors.forename: H
authors.initials: H
authors.lastname: Wedemeyer
authors.forename: M P
authors.initials: MP
authors.lastname: Manns
mesh_terms: D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001219:Aspartate Aminotransferases / Q000097:blood; D001663:Bilirubin / Q000097:blood; D004279:DNA, Viral / Q000097:blood; D005260:Female; D006509:Hepatitis B / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006515:Hepatitis B virus / Q000254:growth & development*; D006801:Humans; D019259:Lamivudine / Q000009:adverse effects / Q000627:therapeutic use*; D017114:Liver Failure, Acute / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D008297:Male; D008875:Middle Aged; D011517:Prothrombin Time
chemical_list: D000998:Antiviral Agents; D004279:DNA, Viral; D019259:Lamivudine; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D001663:Bilirubin